ATE473755T1 - Methode zur herstellung von (poly)peptiden unter verwendung von verkürzten varianten von sv40 large t antigen mit einem intakten n terminus - Google Patents

Methode zur herstellung von (poly)peptiden unter verwendung von verkürzten varianten von sv40 large t antigen mit einem intakten n terminus

Info

Publication number
ATE473755T1
ATE473755T1 AT06025571T AT06025571T ATE473755T1 AT E473755 T1 ATE473755 T1 AT E473755T1 AT 06025571 T AT06025571 T AT 06025571T AT 06025571 T AT06025571 T AT 06025571T AT E473755 T1 ATE473755 T1 AT E473755T1
Authority
AT
Austria
Prior art keywords
poly
peptide
fusion protein
polynucleotide
present
Prior art date
Application number
AT06025571T
Other languages
English (en)
Inventor
Hansjoerg Reimann
Reinhold Schirmbeck
Original Assignee
Rhein Biotech Proz & Prod Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhein Biotech Proz & Prod Gmbh filed Critical Rhein Biotech Proz & Prod Gmbh
Application granted granted Critical
Publication of ATE473755T1 publication Critical patent/ATE473755T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
AT06025571T 1998-10-02 1998-10-02 Methode zur herstellung von (poly)peptiden unter verwendung von verkürzten varianten von sv40 large t antigen mit einem intakten n terminus ATE473755T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP1998/006298 WO2000020606A1 (en) 1998-10-02 1998-10-02 Method for the production of (poly)peptides by using truncated variants of the sv40 large t antigen with an intact n terminus
EP98950105A EP1117803B1 (de) 1998-10-02 1998-10-02 Methode zur herstellung von (poly)peptiden unter verwendung von verkürzten varianten von sv40 'large' t antigen mit einem intakten n terminus

Publications (1)

Publication Number Publication Date
ATE473755T1 true ATE473755T1 (de) 2010-07-15

Family

ID=8167086

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98950105T ATE348177T1 (de) 1998-10-02 1998-10-02 Methode zur herstellung von (poly)peptiden unter verwendung von verkürzten varianten von sv40 'large' t antigen mit einem intakten n terminus
AT06025571T ATE473755T1 (de) 1998-10-02 1998-10-02 Methode zur herstellung von (poly)peptiden unter verwendung von verkürzten varianten von sv40 large t antigen mit einem intakten n terminus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT98950105T ATE348177T1 (de) 1998-10-02 1998-10-02 Methode zur herstellung von (poly)peptiden unter verwendung von verkürzten varianten von sv40 'large' t antigen mit einem intakten n terminus

Country Status (6)

Country Link
EP (2) EP1117803B1 (de)
AT (2) ATE348177T1 (de)
AU (1) AU9629498A (de)
CA (1) CA2344993C (de)
DE (2) DE69841767D1 (de)
WO (1) WO2000020606A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ233799A0 (en) * 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
US7094884B2 (en) 2001-06-22 2006-08-22 Roche Diagnostics Corporation Soluble complexes of amylod β peptide and peptidyl prolyl isomerase chaperone and methods of making and using them
US6962982B2 (en) 2001-06-22 2005-11-08 Roche Diagnostics Corporation Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them
ATE522603T1 (de) 2001-06-22 2011-09-15 Hoffmann La Roche Löslicher komplex, der retrovirale oberflächen- glykoproteine und fkpa oder slyd enthält
US7094757B2 (en) 2001-06-22 2006-08-22 Roche Diagnostics Corporation Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them
AU2002362447A1 (en) * 2001-10-03 2003-04-14 University Of Rochester Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
US20050130259A1 (en) * 2002-06-25 2005-06-16 Akira Ideno Expression vector, host, fused protein, process for producing fused protein and process for producing protein
EP2929045B1 (de) 2012-12-05 2020-12-02 SOLA Biosciences LLC Proteinexpressionsverstärkende polypeptide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019091A1 (en) * 1992-03-18 1993-09-30 Amrad Corporation Limited Tripartite fusion proteins of glutathione s-transferase

Also Published As

Publication number Publication date
DE69836647D1 (de) 2007-01-25
ATE348177T1 (de) 2007-01-15
EP1806142A1 (de) 2007-07-11
EP1117803B1 (de) 2006-12-13
WO2000020606A1 (en) 2000-04-13
DE69841767D1 (de) 2010-08-26
EP1806142B1 (de) 2010-07-14
AU9629498A (en) 2000-04-26
CA2344993C (en) 2012-11-13
EP1117803A1 (de) 2001-07-25
CA2344993A1 (en) 2000-04-13

Similar Documents

Publication Publication Date Title
US4952395A (en) Mycobacterial recombinants and peptides
AU667578B2 (en) Retro-, inverso-, and retro-inverso synthetic peptide analogues
CA2297786A1 (en) New immunoprotective influenza antigen and its use in vaccination
ATE279947T1 (de) Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
EP0751992A4 (de) Vaskularer endothelialer wachstumsfaktor 2
BR9307510A (pt) Molécula de ácido nucleico purificada e isolada plasmídeo recombinante adaptado para transformação de hospedeiro vector recombinante adaptado para transformação de célula hospedeira proteína purificada e isolada proteína de membrana externa d15 peptídio sintético molécula quimérica composição imunogênica e anti-soro ou anticorpo
WO1995029193A3 (en) Melanoma antigens
EP0330506A3 (de) VLA-Proteine
FR2655990A1 (fr) Agent viral responsable de l'hepatite non-a non-b et polypeptides derives de celui-ci utiles pour le diagnostic et la vaccination.
DE60125751D1 (de) Zusammensetzungen und verfahren zur behinderung der vervielfältigung von hiv-1
DK175843B1 (da) Polypeptider af overfladeaktive alvelolarproteiner (ASP), farmaceutisk sammensætning indeholdende polypeptidet, DNA-ekspressionssystem der koder for polypeptidet, samt fremgangsmåde til fremstilling af polypeptider med ASP-aktivitet
ES2297855T3 (es) Anticuerpos monoclonales contra la hepatitis b.
DE69841767D1 (de) Methode zur Herstellung von (Poly)peptiden unter Verwendung von verkürzten Varianten von SV40 Large T antigen mit einem intakten N Terminus
ATE225668T1 (de) Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
RU2009112721A (ru) Частицы с расщепленным ядром, предназначенные для презентации чужеродных молекул, прежде всего для применения в вакцинах, и способ их получения
GR3018371T3 (en) Method for identifying or determining proteins and applications therefor.
DE60131413D1 (de) Verfahren zum auffinden von peptiden zur verwendung in der immuntherapie
CA2240409A1 (en) Mammalian cx3c chemokine genes
ATE327251T1 (de) Methode zur reduzierung der immunogenizität von staphylokinase durch entfernen von t-zell epitopen
JPH089636B2 (ja) Ｈｔｌｖ−ｉｉｉ／ｌａｖウイルス関連ペプチド
CA2075366A1 (en) Immunologically active peptides or polypeptides from the parvovirus b19
Horváth et al. Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage
EP0369816A3 (de) Gegen menschliches polymorphes epitheliales Muzin spezifische monoklonale Antikörper
EP0177814A3 (de) Antikörper gegen Peptide und ihre Verwendung zum Nachweis von Onkogene-Produkten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties